Cart
sales@molnova.com
Boc-NH-PEG3-CH2COOH
CAS No. 462100-06-7
Boc-NH-PEG3-CH2COOH( —— )
Catalog No. M24415 CAS No. 462100-06-7
Boc-NH-PEG3-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 75 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBoc-NH-PEG3-CH2COOH
-
NoteResearch use only, not for human use.
-
Brief DescriptionBoc-NH-PEG3-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC
-
DescriptionBoc-NH-PEG3-CH2COOH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPEGs|Alkyl/ether
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number462100-06-7
-
Formula Weight307.34
-
Molecular FormulaC13H25NO7
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (325.37 mM)
-
SMILESO=C(OC(C)(C)C)NCCOCCOCCOCC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Vollmer S, et al. Design, Synthesis, and Biological Evaluation of MEK PROTACs. J Med Chem. 2020 Jan 9;63(1):157-162.
molnova catalog
related products
-
Fmoc-Val-Cit-PAB-MMA...
Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
-
Azido-PEG2-C6-Cl
Azido-PEG2-C6-Cl is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.
-
Sirt2-PROTAC-1
A novel SirReal-based PROTAC that induces isotype-selective Sirt2 degradation (IC50=0.25 uM).
